A case of clinically amyopathic dermatomyositis that developed during anti-TNF-α therapy for rheumatoid arthritis

Takata, Miyako; Yamasaki, Akira; Yamada, Nanako; Hagino, Hiroshi; Funaki, Yoshihiro; Harada, Tomoya; Okazaki, Ryo; Hasegawa, Yasuyuki; Fukushima, Takehito; Morita, Masato; Sueda, Yuriko; Yamamoto, Akihiro; Shimizu, Eiji

doi:10.1016/j.alit.2017.09.001

Cited by 13 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These scores may be skewed lower given the number of cases with cancer as a possible cause for DM. Reference lists of 114 eligible articles revealed 20 additional articles that were included. Among 134 articles, data from 165 patients were included in the systematic review (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Causes and Clinical Presentation of Drug-Induced Dermatomyositis

Caravan,

Lopez,

Yeh

2024

JAMA Dermatol

View full text Add to dashboard Cite

ImportanceWhile several medications are known to induce dermatomyositis (DM), most existing studies are case reports or small case series from a single institution. There is also limited information on DM induced by immune checkpoint inhibitors, which are increasingly used in oncologic therapy.ObjectiveTo characterize causes and clinical presentation of drug-induced DM based on the current literature.Evidence ReviewA systematic review was performed in PubMed according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines, from inception to August 22, 2022. Articles meeting preestablished inclusion criteria (written in English and classified as original articles, case reports, literature reviews, and observation letters) were selected and data abstracted. Articles that met the scope of the review were also added from reference lists. When possible, study results were quantitatively combined.FindingsIn 134 studies (114 from the literature search and 20 additional studies pulled from reference lists) describing 165 cases, 88 patients (53.3%) were female, and the median (IQR) age was 61 (49-69) years. Among the cases of drug-induced DM, the most common associated medications were hydroxyurea (50 [30.3%]), immune checkpoint inhibitors (27 [16.4%]), statins (22 [13.3%]), penicillamine (10 [6.1%]), and tumor necrosis factor inhibitors (10 [6.1%]). Histopathologic testing, when undertaken, helped establish the diagnosis. There was a median (IQR) of 60 (21-288) days between drug initiation and drug-induced DM onset. History of cancer was reported in 85 cases (51.6%).Conclusions and RelevanceIn this systematic review, drug-induced DM was associated with multiple types of medications, including chemotherapies and immunotherapies. It is essential that dermatologists promptly recognize and diagnose drug-induced DM so that they can guide management to minimize interruption of therapy when possible.

show abstract

Section: Resultsmentioning

confidence: 99%

Causes and Clinical Presentation of Drug-Induced Dermatomyositis

Caravan,

Lopez,

Yeh

2024

JAMA Dermatol

View full text Add to dashboard Cite

show abstract

“…Although several authors showed an efficacy of TNF-α inhibitor, cases of exacerbation and even fatalities have also been described. 3 , 4 , 5 , 6 Moreover, induction of dermatomyositis by TNF-α inhibitor has been reported as well, with most inductions in rheumatoid arthritis patients. 7 The most common TNF-α inhibitor associated with dermatomyositis is etanercept, followed by adalimumab and infliximab.…”

Section: Discussionmentioning

confidence: 97%

Dermatomyositis–lupuslike syndrome overlap under treatment with etanercept for rheumatoid arthritis

et al. 2020

View full text Add to dashboard Cite

“…In addition, several cases of anti-TNF-mediated dermatomyositis/polymyositis have been described [33]. Here, the pathophysiological mechanism is unknown, but increasing interferon-gamma levels following therapy could represent a crucial risk factor [34].…”

Section: Other Skin Manifestationsmentioning

confidence: 99%

Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases

Lopetuso

Cuomo

Mignini

et al. 2023

IJMS

View full text Add to dashboard Cite

Anti-tumour necrosis factor (TNF)-α agents have been increasingly used to treat patients affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory disorders. However, the widening use of biologics is related to a new class of adverse events called paradoxical reactions. Its pathogenesis remains unclear, but it is suggested that cytokine remodulation in predisposed individuals can lead to the inflammatory process. Here, we dissect the clinical aspects and overall outcomes of autoimmune diseases caused by anti-TNF-α therapies.

show abstract

A case of clinically amyopathic dermatomyositis that developed during anti-TNF-α therapy for rheumatoid arthritis

Cited by 13 publications

References 10 publications

Causes and Clinical Presentation of Drug-Induced Dermatomyositis

Causes and Clinical Presentation of Drug-Induced Dermatomyositis

Dermatomyositis–lupuslike syndrome overlap under treatment with etanercept for rheumatoid arthritis

Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases

Contact Info

Product

Resources

About